Fentanyl and its analogs desensitize the cloned mu opioid receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1207-1218

  Bot, George ^a   Blake, Allan D ^a   Li, Shuixing ^a   Reisine, Terry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLIC AMP; FENTANYL; FENTANYL DERIVATIVE; LEVORPHANOL; LOFENTANIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M2; MORPHINE; MU OPIATE RECEPTOR; MUTANT PROTEIN; NALBUPHINE; SUFENTANIL; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CELL CULTURE; CHEMICAL MUTAGENESIS; DRUG POTENCY; DRUG TOLERANCE; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANALGESICS, OPIOID; ANIMALS; CELLS, CULTURED; CYCLIC AMP; FENTANYL; MICE; MUTAGENESIS; RECEPTORS, OPIOID, MU; SUFENTANIL; TRANSFECTION;

EID: 0031837253     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Arden JR, Segredo V, Wang Z, Lameh J and Sadee W (1995) Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor in HEK293 cells. J Neurochem 65:1636-1645.
2. Benovic JL, Staniszewski C, Mayor F, Caron MG and Lefkowitz RJ (1988) Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J Biol Chem 263:3893-3897.
3. Blake AD, Bot G, Li S, Freeman J and Reisine T (1997a) Differential opioid agonist regulation of the mouse μ-opioid receptor. J Biol Chem 272:782-790.
4. Blake AD, Bot G, Tallent M, Law SF, Li S, Freeman J and Reisine T (1997b) Molecular regulation of opioid receptors. Receptors and channels 5:231-235.
5. Bot G, Blake AD, Li S and Reisine T (1997) Opioid regulation of the mouse δ-opioid receptor expressed in human embryonic kidney 293 cells. Mol Pharmacol 52:272-281.
6. Busquets X, Escribe P, Sastre M and Garcia-Sevialla JA (1995) Loss of protein kinase C-alpha beta in brain of heroin addicts and morphine dependent rats. J Neurochem 64:247-252.
7. Chen CA and Okayama H (1988) Calcium phosphate-mediate gene transfer: A high efficient transfection system for stable transforming cells with plasmid DNA. Biotechniques 6:632-638.
8. Costa EM, Hoffman BB and Loew GH (1992) Opioid agonists binding and responses in SH-SY5Y cells. Life Sci 50:73-81.
9. 353, located within the COOH-terminal tail of the d opiate receptor, is involved in receptor down-regulation. J Biol Chem 271:4073-4076.
10. Fleming LM, Ponjee G and Childers SR (1992) Inhibition of protein phosphorylation by opioid-inhibited adenylyl cyclase in rat brain membranes. J Pharmacol Exp Ther 260:1416-1424.
11. X/Z transducer proteins in mouse periaqueductal gray matter. J Pharmacol Exp Ther 281:549-557.
12. 1A receptor. Biochemistry 33:4283-4290.
13. Gintzler AR and Xu H (1991) Different G proteins mediate the opioid inhibition or enhancement of evoked [5-methione]-enkephalin release. Proc Natl Acad Sci USA 88:4741-4745.
14. Heerding J, Raynor K, Kong H, Yu L and Reisine T (1994) Mutagenesis reveals that agonists and peptide antagonists bind in fundamentally distinct manners to the rat mu receptor than do nonpeptide antagonists. Regul Peptides 54:119-120.
15. Janssen PA (1965) 1-Aralkyl-4-(n-aryl-carbonyl-amino)-piperidines and related compounds. U.S. Pat. Off. 3, 164, 600.
16. Janssen PAJ (1982) Potent new analgesics, taylor-made for different purposes. Acta Anaesthes Scand 26:262-268.
17. Kaufman DL, Keith DE, Anton B, Tian J, Magendoz K, New,am D, Tran TH, Lee DS, Wen C, Xia Y-R, Lussis JA and Evans CJ (1995) Characterization of the murine μ opioid receptor gene. J Biol Chem 270:15877-15883.
18. Kenakin T (1995) Agonist-receptor efficacy. I. Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
19. Keith D, Murray SR, Zaki P, Chu PC, Lissin D, Kang L, Evans CJ and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
20. Lambert DG, Atcheson R, Hirst RA and Rowbotham DJ (1993) Effects of morphine and its metabolites on opiate receptor binding, cAMP formation and [3H]noradrenaline release from SH-SY5Y cells. Biochem Pharmacol 46:1145-1150.
21. Lee S-C, Wang J-J, Ho S-T and Tao P-L (1997) Nalbuphine coadministered with morphine prevents tolerance and dependence. Anesth Analg 84:810-815.
22. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179:171-188.
23. q. J Biol Chem 268:13900-13905.
24. Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C and Loew G (1992) Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur J Pharmacol 213:219-225.
25. Nestler EJ (1992) Molecular mechanisms of drug addiction. J Neurosci 12:2439-2450.
26. Nestler EJ, Hope BT and Widnell KL (1993) Drug addiction: A model for the molecular basis of neural plasticity. Neuron 11:995-1106.
27. Noble F and Cox BM (1996) Differential desensitization of mu- and delta-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 117:161-169.
28. + channel-acting drugs. Br J Pharmacol 114:1296-1302.
29. Paix A, Coleman A, Lees J, Grigson J, Brooksbank M, Thorne D and Ashby M (1995) Subcutaneous fentanyl and sufentanil infusion substitution for morphine tolerance in cancer pain management. Pain 63:263-269.
30. Paronis CA and Holtzman SG (1992) Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262:1-9.
31. α subunit and is similar to that of other opioid receptors. Mol Brain Res 29:336-346.
32. Raffa RB, Martinez RP and Connelly CD (1994) G-protein antisense oligodeoxyribo-nucleotides and μ-opioid supraspinal antinociception. Eur J Pharmacol 258:R5-R7.
33. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI and Reisine T (1994) Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol 45:330-334.
34. Reisine T and Bell G (1993) Molecular biology of the opiate receptors. Trends Neurosci 16:506-510.
35. Reisine T and Pasternak G (1996) Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics (Hardman JG, Limbard LE, Molinoff PB, Ruddon RW and Gilman AG eds) pp 521-555, McGraw-Hill, New York.
36. Self DW, McClenahan AW, Beitner-Johnson D, Terwilliger RZ and Nestler EJ (1995) Biochemical adaptations in the mesolimbic dopamine system in response to heroin self-administration. Synapse 21:312-318.
37. Standifer KM, Rossi GC and Pasternak GW (1996) Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein α subunits. Mol Pharmacol 50:293-298.
38. Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB and Uhl GR (1994) -m opiate receptor: Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 269:20548-20553.
39. Tota MR and Schimerlik MI (1990) Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system. Mol Pharmacol 37:996-1004.
40. Walker EA and Young AM (1993) Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine. J Pharmacol Exp Ther 267:322-330.
41. Zacny JP, Conley K and Marks S (1997) Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. J Pharmacol Exp Ther 280:1159-1169.